Skip to main content
TipRanks
Go Ultimate75% OFF

Sartorius Stedim Biotech (DIM) Stock Price & Analysis

20 Followers

DIM Stock Chart & Stats

€225.20€2.00(0.90%)
At close: 5:30 PM GMT+1
€180€200€220Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
EUR 223.60 - EUR 226.60
52-Week Range
EUR 150.00 - EUR 229.80
Previous Close
EUR 223.20
Volume
N/A
Average Volume (3M)
94.44K
Market Cap
EUR 21.92B
Enterprise Value
EUR 22.86B
Total Cash (Recent Filing)
EUR 172.00M
Total Debt (Recent Filing)
EUR 2.31B
Price to Earnings (P/E)
67.4
Beta
1.31
Next Earnings
Feb 23, 2027 (Est.)
Dividend Yield
0.31%

Bulls Say, Bears Say

Bulls Say

Recurring Consumables And Installed Base

The mix of frequently replaced consumables and installed equipment creates repeat purchasing beyond one-time capital sales. As biopharmaceutical customers expand production, this model can support durable customer relationships, recurring revenue, and greater visibility across future manufacturing cycles.

Healthy Operating Margins

Gross and EBITDA margins remain healthy for the business, indicating meaningful value creation from its bioprocessing technologies, equipment, and consumables. These margins provide operating capacity to support research, product development, customer service, and growth investment over the next several quarters.

Improved Financial Stability

The substantial reduction in debt-to-equity strengthens the balance sheet relative to 2023 and improves financial flexibility. Higher equity and lower relative leverage should make it easier to fund operations and strategic investment while reducing the balance-sheet strain associated with prior debt levels.

Bears Say

Weak Cash Conversion

Positive operating and free cash flow are not converting efficiently from reported earnings, which reduces the quality and flexibility of profit generation. If this pattern persists, the company may have less internally generated cash available for investment, debt reduction, or shareholder returns.

Volatile Earnings Recovery

The recovery demonstrates improvement, but the multi-year earnings profile remains volatile and is still described as being in a rebuild phase. Performance below the 2022 peak means future results remain sensitive to the pace of biopharmaceutical production growth and customer capacity expansion.

Meaningful Debt And Moderate Returns

Although leverage has improved, the remaining debt burden is still material relative to the company’s current return profile. Moderate ROE suggests capital is not yet generating returns comparable with prior highs, limiting the strength of balance-sheet efficiency and leaving less room for execution setbacks.

Sartorius Stedim Biotech News

DIM FAQ

What was Sartorius Stedim Biotech’s price range in the past 12 months?
Sartorius Stedim Biotech lowest stock price was €150.00 and its highest was €229.80 in the past 12 months.
What is Sartorius Stedim Biotech’s market cap?
Sartorius Stedim Biotech’s market cap is €21.92B.
When is Sartorius Stedim Biotech’s upcoming earnings report date?
Sartorius Stedim Biotech’s next earnings report is estimated for Feb 23, 2027 (not yet confirmed), which is in 97 days.
How were Sartorius Stedim Biotech’s earnings last quarter?
Sartorius Stedim Biotech released its earnings results on Oct 22, 2026. The company reported €1.18 earnings per share for the quarter, missing the consensus estimate of €1.209 by -€0.029.
Is Sartorius Stedim Biotech overvalued?
According to Wall Street analysts Sartorius Stedim Biotech’s price is currently Undervalued.
Does Sartorius Stedim Biotech pay dividends?
Sartorius Stedim Biotech pays an annual dividend of €0.69 which represents an annual dividend yield of 0.31%. See more information on Sartorius Stedim Biotech dividends here
What is Sartorius Stedim Biotech’s EPS estimate?
Sartorius Stedim Biotech’s EPS estimate is 1.47.
How many shares outstanding does Sartorius Stedim Biotech have?
Sartorius Stedim Biotech has 97,330,410 shares outstanding.
What happened to Sartorius Stedim Biotech’s price movement after its last earnings report?
Sartorius Stedim Biotech reported an EPS of €1.18 in its last earnings report, missing expectations of €1.209. Following the earnings report the stock price went down -2.878%.
Which hedge fund is a major shareholder of Sartorius Stedim Biotech?
Currently, no hedge funds are holding shares in FR:DIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology